Takuji Okusaka
International University of Health and Welfare
623 Papers
3K Citations
Takuji Okusaka is an academic researcher from International University of Health and Welfare. The author has contributed to research in topics: Medicine & Gemcitabine. The author has an hindex of 67, co-authored 490 publications. Previous affiliations of Takuji Okusaka include National Cancer Research Institute & Kyorin University.
Chat about Author
Papers
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
Masafumi Ikeda,Satoshi Shimizu,Tosiya Sato,Manabu Morimoto,Y. Kojima,Yoshitaka Inaba,Atsushi Hagihara,Masatoshi Kudo,Shoji Nakamori,Shuichi Kaneko,R. Sugimoto,T. Tahara,Takumi Ohmura,Kohichiroh Yasui,Keiko Sato,Hiroshi Ishii,J. Furuse,Takuji Okusaka +17 more
TL;DR: This is the first report of its effectiveness in relation to the overall survival in comparison with that of sorafenib alone in patients with advanced hepatocellular carcinoma.
148
Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis.
Takuji Okusaka,Masafumi Nakamura,Masahiro Yoshida,Masayuki Kitano,Katsuhiko Uesaka,Yoshinori Ito,Junji Furuse,Keiji Hanada,Kazuichi Okazaki +8 more
TL;DR: These guidelines represent the most standard clinical and practical management guidelines at this time in Japan and are an attempt to disseminate the Japanese guidelines worldwide for introducing the Japanese approach for clinical management of pancreatic cancer.
147
Possible detection of pancreatic cancer by plasma protein profiling.
Kazufumi Honda,Yasuharu Hayashida,Tomoko Umaki,Takuji Okusaka,Tomoo Kosuge,Satoru Kikuchi,Mitsufumi Endo,Akihiko Tsuchida,Tatsuya Aoki,Takao Itoi,Fuminori Moriyasu,Setsuo Hirohashi,Tesshi Yamada +12 more
TL;DR: Although a multi-institutional large-scale study will be necessary to confirm clinical significance, the biomarker set identified in this study may be applicable to using plasma samples to diagnose pancreatic cancer.
139
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Masato Ozaka,Hiroshi Ishii,Tosiya Sato,Makoto Ueno,Masafumi Ikeda,Kazuhiro Uesugi,Naohiro Sata,Kouichirou Miyashita,Nobumasa Mizuno,Kunihiro Tsuji,Takuji Okusaka,Junji Furuse +11 more
TL;DR: Modified FOLFIRINOX in this study has an improved safety profile with maintained efficacy in MPC without prophylactic pegfilgrastim, and is the first prospective study of modified FolFIRinoX in Asia.
135
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Makoto Shinoto,Makoto Shinoto,Makoto Shinoto,Shigeru Yamada,Kotaro Terashima,Shigeo Yasuda,Yoshiyuki Shioyama,Hiroshi Honda,Tadashi Kamada,Hirohiko Tsujii,Hiromitsu Saisho,Takehide Asano,Taketo Yamaguchi,Hodaka Amano,Takeshi Ishihara,Masayuki Otsuka,Masamichi Matsuda,Osamu Kainuma,Akihiro Funakoshi,Junji Furuse,Toshio Nakagori,Takuji Okusaka,Hiroshi Ishii,Tatsuya Nagakawa,Shinichiro Takahashi,Shoichi Hishinuma,Masafumi Nakamura,Hirofumi Saito,Kiyoshi Ohara,Shinichi Ohkawa,Masahiro Hiraoka +30 more
TL;DR: Carbon ion RT with concurrent full-dose gemcitabine was well tolerated and effective in patients with unresectable locally advanced pancreatic cancer.
124